• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacology, Biochemistry and Behavior >Isobolographic analysis of the interaction between epidural sufentanil and bupivacaine in rats.
【24h】

Isobolographic analysis of the interaction between epidural sufentanil and bupivacaine in rats.

机译：硬膜外舒芬太尼与布比卡因相互作用的等效线描记法分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The present study was performed to evaluate the nature of the interaction between epidurally administered sufentanil and bupivacaine in producing antinociception in rats. Rats in which epidural catheters had been inserted received epidural injections with bupivacaine and sufentanil. Nociception was tested by use of the tail-withdrawal reaction (TWR) test and the hot-plate test. Isobolographic analyses were performed with fixed and variable dose ratio treatment schedules based on the ED50s and the highest inactive concentrations of the compounds in both tests. In the TWR test, a synergistic interaction was obtained between the two compounds independent of whether a variable dose ratio regimen (with either 0.08 microgram/rat sufentanil or 80 micrograms/rat bupivacaine as the preset component) or a fixed dose ratio of 1/1,000 sufentanil/bupivacaine (based on the individual ED50s) was used. In the hot-plate test, a synergistic interaction was observed only in the variable dose ratio regimen with 0.08 microgram/rat sufentanil as the preset component and in the fixed dose ratio regimen of 1/1,000 sufentanil/bupivacaine (a ratio based on the ED50 values of the TWR test) but not with a ratio of 1/200, as demonstrated by the ED50s of both drugs in the hot-plate test. The interaction between epidurally administered bupivacaine and sufentanil seems to be synergistic for both tests when variable and fixed dose ratios are used. The synergism could be more easily demonstrated in the TWR test. For drugs with a segmental action, the hot-plate test seems to be less optimal. The necessity of a minimal critical amount of bupivacaine to obtain synergism may have clinical implications.
机译：进行本研究以评价硬膜外给药舒芬太尼与布比卡因之间在大鼠产生抗伤害感受中的相互作用的性质。插入硬膜外导管的大鼠接受硬膜外注射布比卡因和舒芬太尼。通过使用尾缩反应（TWR）测试和热板测试来测试伤害感受。根据两个试验中的ED50和化合物的最高非活性浓度，使用固定剂量和可变剂量比的治疗方案进行等效线描记分析。在TWR测试中，两种化合物之间均获得了协同相互作用，而与剂量比可变方案（0.08微克/大鼠舒芬太尼或80微克/大鼠布比卡因为预设成分）还是固定剂量比为1 / 1,000无关使用舒芬太尼/布比卡因（基于单个ED50）。在热板测试中，仅在以0.08微克/大鼠舒芬太尼作为预设成分的可变剂量比方案和1 / 1,000舒芬太尼/布比卡因的固定剂量比方案中观察到协同相互作用（比例基于ED50 （热重试验的TWR值），但比率不为1/200，如热板试验中两种药物的ED50所证明的。当使用可变剂量比和固定剂量比时，硬膜外给予布比卡因和舒芬太尼之间的相互作用对于两种测试似乎是协同的。在TWR测试中可以更容易地证明协同作用。对于具有分段作用的药物，热板测试似乎不是最佳选择。最小临界量的布比卡因获得增效作用的必要性可能具有临床意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号